Which Oral Amylin Analog / GLP-1 Agonist Combinations Show Dose-Ratio Dependent Effects in 2026 Obesity Pipelines?

As of July 2026, Verdiva Bio's Phase 1 study of VRB-103 (oral amylin analog) plus VRB-101 (oral GLP-1 agonist) is the only registered trial explicitly testing multiple fixed dose ratios of an oral amylin/GLP-1 combination. Preclinical amylin/GLP-1 co-dosing literature consistently shows non-linear, ratio-dependent weight-loss responses — a pattern that motivates the multi-ratio Phase 1 design.

Why Does the Amylin-to-GLP-1 Dose Ratio Produce Non-Linear Effects Rather Than Simple Additivity?

Amylin and GLP-1 receptor systems converge on overlapping downstream satiety circuits — area postrema / NTS for amylin, arcuate nucleus for GLP-1 — via anatomically distinct entry points. Preclinical rodent data show that specific molar ratios produce disproportionately larger weight-loss responses than either compound alone at equivalent total peptide mass, a hallmark of receptor-system co-activation rather than simple summation.

The mechanistic basis for ratio-dependence lies in the sequential architecture of the central satiety network. Amylin receptor activation in the area postrema (AP) generates a vagal-afferent signal that reaches the nucleus tractus solitarius (NTS) and then ascends to the hypothalamus. GLP-1R activation in the arcuate nucleus operates on the same downstream melanocortin-4 receptor (MC4R) axis but enters the circuit at a different anatomical node.

When both inputs arrive simultaneously, the MC4R pathway receives convergent signals from two upstream sources. At low amylin-to-GLP-1 ratios, the GLP-1R signal dominates and the amylin contribution is sub-threshold. At high amylin-to-GLP-1 ratios, the reverse occurs. At intermediate ratios, both pathways are sufficiently activated to produce a combined MC4R response that exceeds the sum of each compound's individual contribution.

This ratio-dependence has been documented in rodent models using pramlintide and exendin-4 co-infusion studies, where the optimal molar ratio for maximal food-intake suppression was narrower than expected from additive pharmacology. The implication for oral combination design is that fixed-dose formulations must identify the ratio that sits within the co-activation window — a task requiring a multi-ratio Phase 1 design rather than a single fixed-combination dose escalation.

How Does Verdiva Bio's VRB-103 Plus VRB-101 Phase 1 Design Map the Dose-Ratio Space?

Verdiva Bio's July 2026 Phase 1 study of VRB-103 plus VRB-101 tests multiple fixed dose ratios in a single ascending-dose framework. The multi-ratio design is structured to identify the pharmacokinetically and pharmacodynamically optimal ratio — the point at which both receptor systems achieve sufficient co-activation to produce the supra-additive satiety response seen in preclinical models.

The Phase 1 design is notable for two structural features. First, it tests the combination as an oral formulation — both VRB-103 and VRB-101 are engineered for oral bioavailability, requiring each compound to survive gastric acid exposure, achieve sufficient intestinal absorption, and maintain a pharmacokinetic profile compatible with co-administration. Second, the multi-ratio arm structure allows the study to generate dose-ratio response data within a single trial.

For stack designers, the multi-ratio Phase 1 structure generates three types of data simultaneously: absolute pharmacokinetic exposure for each compound at each ratio, the ratio-dependent pharmacodynamic signal (appetite suppression, gastric emptying, glucose excursion), and the tolerability profile at each ratio. This data architecture maps the interaction space rather than simply establishing a maximum tolerated dose for a single fixed combination.

What Oral Bioavailability Challenges Distinguish Oral Amylin/GLP-1 Combinations From Injectable Predecessors?

Oral peptide delivery introduces a pharmacokinetic variable absent from injectable combinations: differential gastrointestinal absorption rates can shift the effective in vivo dose ratio away from the nominal formulated ratio. An oral amylin analog and an oral GLP-1 agonist with different absorption kinetics will not necessarily achieve the target molar ratio simultaneously, making formulation engineering as critical as dose-ratio selection.

Injectable amylin/GLP-1 combinations — most extensively studied as subcutaneous pramlintide plus exendin-4 in rodent models, and as cagrilintide plus semaglutide in human Phase 3 — achieve predictable plasma ratio profiles because subcutaneous absorption kinetics for each compound are well-characterised and relatively stable. The nominal injected ratio closely approximates the systemic exposure ratio.

Oral peptide formulations face three additional variables that can decouple the nominal ratio from the effective systemic ratio. Gastric acid stability differs between amylin analogs and GLP-1 agonists. Intestinal permeability enhancers — used in oral semaglutide (Rybelsus) and likely in next-generation oral GLP-1 compounds — may differentially affect co-formulated peptides. First-pass hepatic extraction can further alter the ratio between portal and systemic circulation.

These variables explain why Verdiva Bio's Phase 1 design tests multiple ratios rather than a single fixed combination. The formulated ratio is a starting point; the pharmacokinetically effective ratio at the receptor is the variable that determines whether the co-activation window is achieved. Characterising the relationship between formulated ratio and effective systemic ratio is a primary objective of the multi-ratio Phase 1 design.

What Do Injectable Amylin/GLP-1 Combination Precedents Reveal About Ratio-Dependent Co-Activation?

The CagriSema combination produced approximately 22.7% mean weight loss at 68 weeks in REDEFINE-1 versus approximately 15.7% for semaglutide monotherapy — a 7 percentage-point increment attributable to amylin-pathway augmentation at a 1:1 mass ratio. Earlier pramlintide/exendin-4 rodent studies showed that this weight-loss increment was ratio-dependent, with off-ratio combinations producing effects closer to monotherapy.

The REDEFINE-1 trial tested a single fixed ratio and established proof-of-concept for amylin/GLP-1 combination efficacy. It did not characterise the dose-ratio response surface. Whether a different cagrilintide-to-semaglutide ratio would produce greater or lesser weight loss than the 1:1 design remains untested in humans.

Preclinical pramlintide/exendin-4 co-infusion studies in diet-induced obese rats (Trevaskis et al., 2010, Obesity) established that the combined weight-loss response was maximal at a specific molar ratio. The response declined at both higher and lower amylin-to-GLP-1 ratios. A two-fold shift in either direction from the optimal ratio reduced the weight-loss response by approximately 30 to 40% relative to the combined peak.

This preclinical ratio-sensitivity is the direct scientific rationale for the multi-ratio Phase 1 design in oral combination programs. If the co-activation window is as narrow in humans as in rodent models, a single fixed-ratio oral combination has a meaningful probability of missing the optimal ratio. This risk is amplified by the oral bioavailability variables that can shift the effective systemic ratio away from the formulated ratio.

How Does the VRB-103 / VRB-101 Interaction Map Into a 2026 Protocol Blueprint?

The VRB-103 / VRB-101 combination is the only oral amylin/GLP-1 pairing with active Phase 1 multi-ratio data generation as of July 2026. Phase 1 data are not yet public, so no evidence-based ratio recommendation is possible. The interaction class is mappable: non-overlapping primary receptor systems with documented preclinical co-activation, placing the combination in the Proposed Co-Activation tier.

Does the Amylin-to-GLP-1 Ratio Also Determine the Tolerability Profile, Not Just Efficacy?

Yes — preclinical and early clinical data indicate that the amylin-to-GLP-1 dose ratio shapes the tolerability profile independently of total peptide load. Higher amylin-to-GLP-1 ratios shift the adverse-event profile toward area postrema-mediated emesis, while lower ratios shift it toward GLP-1R-mediated gastric-emptying slowing. The optimal ratio must satisfy both the co-activation efficacy window and the tolerability constraint simultaneously.

Amylin-pathway nausea is mechanistically distinct from GLP-1R-mediated nausea. Amylin receptor activation in the area postrema directly stimulates the chemoreceptor trigger zone (CTZ), producing acute emesis that is dose-dependent and rapid in onset. GLP-1R-mediated nausea is primarily driven by gastric emptying slowing, is more gradual in onset, and typically attenuates with dose titration over weeks.

In the CagriSema REDEFINE-1 trial, nausea was reported in approximately 30% of the combination arm versus approximately 21% for semaglutide monotherapy. This 9 percentage-point increment is attributable to the added amylin-pathway component at the 1:1 mass ratio. Whether a lower cagrilintide-to-semaglutide ratio would reduce this nausea increment while preserving the weight-loss increment is an untested question in human data.

For oral combination programs, the tolerability-ratio relationship carries additional complexity. If oral bioavailability of the amylin component is lower and more variable than the GLP-1 component, the effective systemic ratio will be shifted toward the GLP-1 side — potentially reducing amylin-pathway nausea but also reducing the amylin contribution to the combined satiety signal. The Verdiva Bio Phase 1 multi-ratio design will generate the first human data on whether this trade-off is navigable in an oral formulation.

What Are the Binding Evidence Gaps for Oral Amylin/GLP-1 Dose-Ratio Stack Design in 2026?

Four gaps constrain oral amylin/GLP-1 stack design in 2026: no published human pharmacokinetic data for any oral amylin analog combined with an oral GLP-1 agonist; no human dose-ratio response data for any oral amylin/GLP-1 combination; no long-term efficacy or safety data for oral combination formats; and no validated method for predicting effective systemic ratio from formulated ratio in oral co-administration.

The VRB-103 / VRB-101 Phase 1 study is designed to close the first two gaps — human pharmacokinetic exposure data and dose-ratio response characterisation. However, Phase 1 studies are typically powered for safety and pharmacokinetics, not efficacy. Weight-loss effect-size data from the VRB-103 / VRB-101 combination will require Phase 2 confirmation before any protocol-level efficacy claim can be supported.

The third gap — long-term safety — is structurally unavoidable at the Phase 1 stage. The CagriSema injectable combination has 68-week Phase 3 safety data from REDEFINE-1. No oral amylin/GLP-1 combination has any long-term human safety data as of July 2026. Protocol designers working with oral combination formats are operating in an evidence space that is at minimum two to three years behind the injectable combination evidence base.

The fourth gap — predicting effective systemic ratio from formulated ratio — is specific to oral delivery and has no direct precedent in the injectable combination literature. Oral semaglutide (Rybelsus) achieves approximately 1% absolute bioavailability using a SNAC absorption enhancer. Whether a co-formulated oral amylin analog achieves comparable bioavailability in the presence of the same enhancer is unknown and cannot be extrapolated from injectable data.

How Do Retatrutide, Cagrilintide, and Eloralintide Compare on Weight-Loss and Appetite-Suppression Effect Sizes in 2026 Obesity Studies? What Does the 2026 CagriSema Evidence Say About Combining Cagrilintide with Semaglutide for Obesity? How Does Oral Semaglutide Compare to Injectable Formulations for Metabolic Performance in 2026? Does Oral GLP-1 Receptor Agonism Now Have Clinical Proof Beyond Injectable Peptides — How Do 2026 Oral Obesity Trials Compare with Semaglutide and Tirzepatide on Weight Loss and Tolerability? What Do the 2026 Phase 3 TRIUMPH Data Show for Retatrutide's Weight-Loss Efficacy, Cardiometabolic Effects, and Dose-Limiting Adverse Events? What Do 2026 Obesity Analyses Reveal About Retatrutide's Efficacy and Safety Risk-Benefit Profile?